InMed Pharmaceuticals Inc (INM) vs. Its Peers: A Comparison

Additionally, the 36-month beta value for INM is 0.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for INM is 3.28M and currently, short sellers hold a 1.74% ratio of that float. The average trading volume of INM on April 04, 2024 was 160.73K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

INM) stock’s latest price update

InMed Pharmaceuticals Inc (NASDAQ: INM)’s stock price has soared by 19.11 in relation to previous closing price of 0.35. Nevertheless, the company has seen a gain of 20.21% in its stock price over the last five trading days. InvestorPlace reported 2023-10-25 that InMed Pharmaceuticals (NASDAQ: INM ) stock is falling on Wednesday after the pharmaceutical company’s shares underwent a massive rally on Tuesday! INM stock was up 70.5% when normal trading hours ended on Tuesday.

INM’s Market Performance

InMed Pharmaceuticals Inc (INM) has experienced a 20.21% rise in stock performance for the past week, with a 14.85% rise in the past month, and a 3.18% rise in the past quarter. The volatility ratio for the week is 10.07%, and the volatility levels for the past 30 days are at 11.06% for INM. The simple moving average for the past 20 days is 16.49% for INM’s stock, with a -31.52% simple moving average for the past 200 days.

INM Trading at 14.24% from the 50-Day Moving Average

After a stumble in the market that brought INM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.96% of loss for the given period.

Volatility was left at 11.06%, however, over the last 30 days, the volatility rate increased by 10.07%, as shares surge +18.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.48% upper at present.

During the last 5 trading sessions, INM rose by +22.64%, which changed the moving average for the period of 200-days by -65.42% in comparison to the 20-day moving average, which settled at $0.3611. In addition, InMed Pharmaceuticals Inc saw 0.22% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at INM starting from HULL ANDREW, who purchase 37,500 shares at the price of $0.39 back on Feb 21 ’24. After this action, HULL ANDREW now owns 38,258 shares of InMed Pharmaceuticals Inc, valued at $14,625 using the latest closing price.

ADAMS ERIC A, the President & CEO of InMed Pharmaceuticals Inc, purchase 41,600 shares at $0.36 during a trade that took place back on Feb 20 ’24, which means that ADAMS ERIC A is holding 43,959 shares at $14,922 based on the most recent closing price.

Stock Fundamentals for INM

Current profitability levels for the company are sitting at:

  • -1565.5 for the present operating margin
  • 0.34 for the gross margin

The net margin for InMed Pharmaceuticals Inc stands at -1.01. The total capital return value is set at -723.62. Equity return is now at value -46.86, with -39.48 for asset returns.

Based on InMed Pharmaceuticals Inc (INM), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -5.43. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -117382.99.

Currently, EBITDA for the company is -7.73 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of -0.94. The receivables turnover for the company is 16.83for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.

Conclusion

In conclusion, InMed Pharmaceuticals Inc (INM) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts